Testing a new drug combo for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called RBS2418 added to two immunotherapy medicines (tremelimumab and durvalumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the combination helps patients who are starting their first treatment for this stage of liver cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced liver cancer that cannot be removed by surgery and are starting your first treatment for this stage.
- You must be willing to provide a tissue sample (either from a past biopsy or a new one).
- Your liver function must be stable, as measured by a Child-Pugh score of less than B8.
- You cannot have very advanced liver cancer (BCLC stage D) or be eligible for curative treatments like surgery or transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Italian study follows patients with advanced liver cancer (hepatocellular carcinoma) who receive a combination immunotherapy treatment called STRIDE for the first time. The trial tracks how well the treatment works, how it affects quality of life, and its safety in people with moderate to severe liver disease.
This trial tests the drug durvalumab in people with advanced liver cancer (HCC) that has spread beyond the liver and cannot be removed by surgery. It aims to see if durvalumab can help shrink tumors or slow the disease.
This trial tests adding lenvatinib (a targeted therapy pill) to a combination of two immunotherapy drugs (durvalumab and tremelimumab) for people with liver cancer that cannot be removed by surgery. The goal is to see if the three-drug approach works better than the two immunotherapy drugs alone.
This study is looking for people with advanced liver cancer (hepatocellular carcinoma) who have not yet had systemic treatment. Participants will receive a combination of two immunotherapy drugs: tremelimumab and durvalumab (the STRIDE regimen). The goal is to find biomarkers that can predict how well the cancer responds to this treatment.
This trial tests a new drug combination (rilvegostomig plus bevacizumab, with or without tremelimumab) as a first treatment for people with advanced liver cancer (HCC) that cannot be removed by surgery or treated with local therapies. It aims to see if these combinations help shrink tumors or slow disease progression.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
Hear when a new Advanced Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.